Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Journal Scan / Research · July 19, 2022

Effect of ADT on 18F-Fluciclovine PET/CT in the Detection of Prostate Cancer Recurrence and Metastatic Disease Localization

Urologic Oncology: Seminars and Original Investigations

 

Additional Info

Urologic Oncology: Seminars and Original Investigations
Effect of hormonal therapy on 18F-fluciclovine PET/CT in the detection of prostate cancer recurrence, localization of metastatic disease, and correlation with prostate-specific antigen
Urol. Oncol 2022 Jun 20;[EPub Ahead of Print], JE Bulbul, A Hashem, D Grybowski, C Joyce, E Rashad, MS Gabriel, RH Wagner, B Savir-Baruch

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading